255 results on '"Mesia R"'
Search Results
2. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
3. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
4. Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era
5. Comments on “Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines”
6. Human papillomavirus-related oropharyngeal cancer
7. Nutritional changes in patients with locally advanced head and neck cancer during treatment
8. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2)
9. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1)
10. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
11. Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020)
12. SEOM clinical guideline in nasopharynx cancer (2017)
13. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
14. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
15. Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab
16. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
17. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
18. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
19. SEOM-TTCC clinical guideline in nasopharynx cancer (2021)
20. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
21. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines
22. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
23. Relationship between body composition changes and EPA supplementation in patients diagnosed with locally advanced squamous cell carcinoma of the head and neck (la-scchn)
24. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
25. The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy
26. 1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)
27. Unveiling body composition as prognostic factor in metastatic cancer patients (PT) treated with molecularly-targeted agents (MTA) or immunotherapy (IO)
28. Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)
29. Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion
30. SERONCOVID: Seroconversion in solid-tumor cancer patients (p) after COVID-19 diagnosis
31. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
32. 2220P MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
33. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
34. Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy
35. Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients
36. Comparing frailty screening tools for older head and neck cancer patients
37. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
38. Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapy
39. Outcome and toxicity in older patients with locoregionallyadvanced head and neck cancer: Relevance of an oncogeriatric approach
40. Impact of geriatric assessment on the management of older head and neck cancer patients
41. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Δ24RGD
42. PCN226 Defining a Standard Set of Health Outcomes for Patients with Squamous Cell Carcinoma of the Head and Neck in Spain
43. PO-0815: Validation of a Prognostic Model for Predicting Larynx Preservation Outcome in Catalan Population.
44. 318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
45. 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
46. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
47. Needs, Findings and Outcome of Post-Chemotherapy Surgery of Residual Masses (RM) in Patients with Non-Seminomatous Germ Cell Testis Tumours (NSGCTT) at a Single Institution
48. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
49. SUN-PO112: Nutritional and Body Composition Changes During Radical Treatment for Locally Advanced Head and Neck Cancer (LA-HNC) Patients
50. PD-029 Phase II trial: melatonin oral gel for prevention of mucositis in oropharynx and oral cavity tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.